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Over-the-counter drug distribution and tuberculosis control 
in India
Tuberculosis caused by Mycobacterium tuberculosis has 
been catastrophic with one third of world’s population 
infected with tuberculosis bacilli.1 The incidence 
and prevalence of tuberculosis is much higher in 
high-burden countries like India, which accounts 
for 26% of all cases of tuberculosis worldwide.2 The 
implementation of directly observed, treatment-short 
course (DOTS) under the Revised National Tuberculosis 
Control Programme (RNTCP) has been instrumental in 
tuberculosis control in India. In 2015, 1·28 billion people 
were covered under RNTCP with cure rate success of 
more than 85%. Despite high success rates, every year 
almost 2·2 million people develop tuberculosis in India 
and 220 000 people die from the disease.3 An increase in 
the number of drug-resistant cases has added a big blow 
to tuberculosis control programme in India. According 
to WHO, India is home to almost 73 000 drug-resistant 
cases of tuberculosis.4 Irrational over-the-counter drug 
distribution by private pharmacists has been one of the 
key factors aﬀ ecting tuberculosis control programmes 
in the country.
In India, any drugs not included in the list of 
prescription-only drugs are regarded as non-prescribed 
or over-the-counter drugs. In recent years, over-the-
counter drug distribution has increased substantially, 
which is mainly the result of exponential growth 
of pharmaceutical markets in India. In 2011, Indian 
pharmaceutical markets recorded turnover of inter-
national $ (INR$) 538 million, mostly because of in-
creasing investments by domestic and international 
companies in rural markets and through sale of over-
the-counter drugs.5 Despite high over-the-counter drug 
prevalence in India, few studies have been done of their 
eﬀ ect on tuberculosis control. 
In The Lancet Infectious Diseases, Madhukar Pai and 
colleagues6 used the standardised patient method 
to access over-the-counter antibiotic distribution 
by pharmacists in urban India. The two categories 
of standardised patients, which included both 
symptomatic and microbiology conﬁ rmed tuberculosis 
cases, visited 623 diﬀ erent pharmaceutical settings 
in urban areas of the cities Delhi, Mumbai, and Patna. 
These patients were used to screen quality of ideal 
management along with over-the-counter drug 
distribution. The results of the study suggested better 
management of conﬁ rmed cases than suspected cases, 
by urban pharmacies, wherein 372 (62%) of 601 cases 
(95% CI 58–66) were ideally managed and referred to 
health-care centres without any drug dispensing. On 
the contrary, only 99 (15%) of 599 pharmacies ideally 
managed presumptive cases, and only 80 (13%) of 
599 (95% CI 11–16) cases underwent referrals. The 
results showed a substantial eﬀ ect on tuberculosis 
management, based on referral rates of patients to 
health centres. Low referral rates of suspected cases 
only show high over-the-counter drug abuse in these 
patients, thereby increasing the risk of drug resistance 
before initiation of treatment. 
Our experience of working in high tuberculosis 
endemic settings and other studies in high-burden 
countries7–9 support the above conclusion made by Pai 
and colleagues, when over-the-counter drug distri-
bution is commonly encountered. India has many 
pockets of tuberculosis endemics inhabited mainly by 
rural population. High illiteracy further compounds the 
problem because most people without any knowledge 
of tuberculosis infection directly approach private 
pharmacies for medicines. Most pharmacies do not have 
any trained staﬀ  and pharmacists often leave the shop 
in care of subordinates to distribute drugs. Therefore 
treatment and reporting practices often do not meet 
national or international standards for tuberculosis. 
Because of these reasons, only 58% of total tuberculosis 
cases are notiﬁ ed in India every year, with one third of 
cases being either no t diagnosed or diagnosed but not 
treated properly.10
Although the studies by Pai and colleagues are 
admirable and project need of antimicrobial stewardship 
in tuberculosis control in India, we feel that additional 
studies, especially in rural and underdeveloped regions 
targeting local pharmaceuticals, would further bolster 
our understanding of over-the-counter drug abuse in 
this population.  
Private pharmacies play a crucial part in tuberculosis 
control. In 2003, India launched nationwide public– 
private mix DOTS programme to boost private 
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pharmacies in treatment and observation along 
with increased referral rates to health centres.11 In 
2013, the Cosmetic and Drug Act launched by the 
Indian union health ministry prohibited the sale of 
any antibiotics or anti-tuberculosis drug without 
a referral from a medical practioner.12 Despite 
sustainable efforts, the link between the public sector 
and private pharmacies remains underdeveloped. 
A legislative and educational strategy is required in 
underdeveloped regions to prevent the misuse of 
antibiotics and to reduce cases of drug resistance. In 
the near future, increased advocacy in non-referring 
pharmacies is needed to boost the DOTS programme 
in India. 
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Getting bang for buck in the latent tuberculosis care cascade
An important component of the strategy to reduce 
and eliminate tuberculosis, as outlined by WHO in their 
post-2015 strategy, is to target preventative therapy at 
those with presumed latent tuberculosis infection at 
high risk of future active tuberculosis.1 In low-burden 
settings it makes sense to target some groups for 
screening such as close contacts of index cases with active 
tuberculosis, immigrants from high-burden countries, 
and other vulnerable subpopulations who are high risk 
of infection.1 Indeed, reactivation of latent tuberculosis 
infection could account for more than 80% of incident 
cases in such settings.2 By contrast, in high-burden 
settings, identiﬁ cation and treatment of infectious 
active tuberculosis cases remains the priority, and the 
sheer burden of disease and limitation of resources mean 
that only certain groups at high risk for progression, 
such as children and people with HIV, are targeted for 
preventative therapy.1  Nevertheless, uptake of screening 
and preventative therapy in HIV-infected people from 
tuberculosis-endemic countries has been poor3 despite 
recommendations that tuberculin skin testing (TST) not 
be a prerequisite for preventative therapy, even though it 
enables better targeting of treatment.4 Thus, in both high-
burden and low-burden settings, targeted preventa tive 
treatment is an important strategy for tuberculosis 
control. However, once identiﬁ ed, what proportion of this 
target population undergo medical evaluation, are tested 
for latent tuberculosis, return for initiation of preventative 
therapy, and complete therapy; and how much attrition 
occurs at each step and throughout the process? 
These important questions, hitherto not collectively 
and systematically addressed, are the subject of a 
systematic review and meta-analysis by Hannah Alsdurf 
and colleagues5 in The Lancet Infectious Diseases. The 
authors collectively refer to these individual steps, from 
identiﬁ cation of a target population to the completion 
of preventative therapy, as the latent tuberculosis 
infection cascade. 
Alsdurf and colleagues found that, although 
documented, only 18·8% (95% CI 16·3–19·7) of those 
estimated to have presumed latent tuberculosis infection 
completed preventative treatment.5 Thus, despite some 
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